drugset / Trial / NCT07459647
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
NaSingle-groupOpen-labelTreatment
Summary
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
Timeline
- Start
- 2026-03-31
- Primary completion
- 2030-02
- Completion
- 2030-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ML-007C-MA | Unknown | 210 mg | — |